Novo Nordisk A/S $NVO Shares Sold by Stiles Financial Services Inc

Stiles Financial Services Inc trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 63.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,640 shares of the company’s stock after selling 20,038 shares during the period. Stiles Financial Services Inc’s holdings in Novo Nordisk A/S were worth $592,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in NVO. Franklin Resources Inc. increased its position in shares of Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors increased its position in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $310,199,000. Clear Street Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $56,378,000. Finally, Armistice Capital LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $40,841,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill demand is surging, with reports of a “record-breaking” U.S. launch and more than 2 million prescriptions since January, strengthening confidence in Novo Nordisk’s growth outlook. Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
• Positive Sentiment: Novo Nordisk raised its 2026 guidance after strong oral Wegovy prescriptions, suggesting the new formulation could offset some pricing pressure and support profits. Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
• Positive Sentiment: Amazon is expanding access to Novo Nordisk’s Ozempic pill through same-day delivery and kiosks, which could broaden patient reach and improve adoption. Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
• Positive Sentiment: Analysts are lifting earnings estimates, reflecting confidence that the company’s recent momentum can carry into the next fiscal year. Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)
• Neutral Sentiment: Novo’s India sales jumped after price cuts boosted demand, but the growth also highlights intensifying competition from cheaper GLP-1 alternatives in key international markets. Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
• Neutral Sentiment: Broader investor focus remains on whether the Wegovy pill can expand the GLP-1 market enough to offset pricing pressure and competition from Eli Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Generic Ozempic competition is beginning to emerge in Canada, raising concern that semaglutide revenue could weaken internationally over time. Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Novo Nordisk A/S Price Performance

Shares of NVO opened at $46.02 on Friday. The business’s 50-day moving average is $38.71 and its two-hundred day moving average is $46.97. The company has a market capitalization of $205.47 billion, a P/E ratio of 10.80, a P/E/G ratio of 10.74 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.57 and a current ratio of 0.79. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Research analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NVO shares. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.